Ramón García Sanz-rekin lankidetzan egindako argitalpenak (57)

2024

  1. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2023

  1. Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia

    Leukemia, Vol. 37, Núm. 2, pp. 388-395

  2. Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

    Cancers, Vol. 15, Núm. 14

  3. Multiple myeloma with t(11;14): impact of novel agents on outcome

    Blood Cancer Journal, Vol. 13, Núm. 1

  4. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

    Cancers, Vol. 15, Núm. 5

  5. Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: Update on laboratory tests for the study of monoclonal gammopathies

    Clinical Chemistry and Laboratory Medicine, Vol. 61, Núm. 12, pp. 2115-2130

  6. Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part II: Methodological and clinical recommendations for the diagnosis and follow-up of monoclonal gammopathies

    Clinical Chemistry and Laboratory Medicine, Vol. 61, Núm. 12, pp. 2131-2142

2022

  1. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma

    Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871

  2. MM-202 Impact of t(11;14) in Multiple Myeloma on Response to Treatment and Survival

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S413-S414

  3. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

  4. Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival

    British Journal of Haematology, Vol. 198, Núm. 2, pp. 278-287

2021

  1. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852

  2. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  3. Genetic complexity impacts the clinical outcome of follicular lymphoma patients

    Blood Cancer Journal

  4. Immune system alterations in multiple myeloma: Molecular mechanisms and therapeutic strategies to reverse immunosuppression

    Cancers, Vol. 13, Núm. 6, pp. 1-26

2020

  1. A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients

    Journal of Molecular Diagnostics, Vol. 22, Núm. 1, pp. 60-71

  2. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  3. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

  4. Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder

    Leukemia and Lymphoma

  5. Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients

    British Journal of Haematology, Vol. 189, Núm. 4, pp. 718-730